Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Large Growth in Short Interest

Aadi Bioscience, Inc. (NASDAQ:AADI - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 547,500 shares, a growth of 136.0% from the December 31st total of 232,000 shares. Based on an average daily trading volume, of 322,600 shares, the short-interest ratio is currently 1.7 days. Approximately 2.7% of the company's shares are sold short.

Hedge Funds Weigh In On Aadi Bioscience

Several institutional investors have recently added to or reduced their stakes in AADI. BML Capital Management LLC acquired a new stake in Aadi Bioscience in the third quarter worth $4,120,000. Peapod Lane Capital LLC acquired a new position in Aadi Bioscience during the 4th quarter worth approximately $1,397,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Aadi Bioscience in the second quarter worth approximately $37,000. Finally, XTX Topco Ltd acquired a new stake in Aadi Bioscience in the 3rd quarter valued at $32,000. 52.08% of the stock is owned by institutional investors and hedge funds.

Aadi Bioscience Stock Performance

AADI stock remained flat at $2.88 during midday trading on Friday. 112,567 shares of the company traded hands, compared to its average volume of 243,399. The firm has a market cap of $70.99 million, a price-to-earnings ratio of -1.26 and a beta of 0.65. The company's fifty day moving average price is $2.84 and its two-hundred day moving average price is $2.18. Aadi Bioscience has a 1-year low of $1.21 and a 1-year high of $3.81.

Aadi Bioscience (NASDAQ:AADI - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.46). Aadi Bioscience had a negative return on equity of 71.87% and a negative net margin of 246.06%. The company had revenue of $7.21 million for the quarter, compared to the consensus estimate of $6.55 million. During the same period in the previous year, the business earned ($0.60) EPS. Analysts predict that Aadi Bioscience will post -2.04 EPS for the current fiscal year.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.